

AMENDMENTS

Please amend claims as follows:

Claims 1-25 (Cancelled).

26. (Currently amended). A method of treating a tumor in an animal which comprises administering to said animal a tumor inhibiting effective amount of an antigen-presenting cell, wherein said antigen-presenting cell expresses at least one class I MHC or class II MHC determinant that is syngeneic to said animal and at least one class I or II MHC determinant that is allogeneic to said animal, wherein said antigen-presenting cell is selected from the group consisting of professional antigen-presenting cells and facultative antigen-presenting cells, and wherein said antigen-presenting cell is transfected with ~~the~~ total genomic DNA isolated from the tumor cells of said animal.

Claims 27-40 (cancelled).

41. (Previously presented). The method according to claim 26, wherein said antigen presenting cell is further transfected with a nucleic acid molecule coding for at least one cytokine.

42. (Previously presented) The method of claim 41, wherein said cytokine is selected from the group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interferon- α , interferon- γ , tumor necrosis factor, granulocyte macrophage colony stimulating factor, and granulocyte colony stimulating factor.

43. (Previously presented). The method according to claim 26, wherein said antigen-presenting cell is selected from the group consisting of a fibroblast, a macrophage, a B cell, and a dendritic cell.

44. (Previously presented). The method according to claim 26, wherein said tumor is a solid tumor or a hematological tumor.

45. (Previously presented). The method of claim 44, wherein said tumor is selected from the group consisting of melanoma, lymphoma, plasmacytoma, sarcoma, glioma, thymoma, leukemias, breast cancer, prostate cancer, colon cancer, esophageal cancer, brain cancer, lung cancer, ovarian cancer, cervical cancer and hepatoma.

46. (Previously presented). The method according to claim 26, wherein said animal is a human subject.

47. (Currently amended). A method of inhibiting tumor cell growth in an animal which comprises administering to said animal a tumor-inhibiting effective amount of an antigen-presenting cell, wherein said antigen presenting cell expresses at least one class I MHC or class II MHC determinant that is syngeneic to said animal and at least one class I or II MHC determinant that is allogeneic to said animal, wherein said antigen-presenting cell is selected from the group consisting of professional antigen-presenting cells and facultative antigen-presenting cells, and wherein said antigen-presenting cell is transfected with **total** genomic DNA isolated from the tumor cells of said animal.

48. (Previously presented). The method of claim 47, wherein said antigen presenting cell is further transfected with a nucleic acid molecule coding for at least one cytokine.

49. (Previously presented). The method of claim 47, wherein said cytokine is selected from the group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interferon- α , interferon- γ , tumor necrosis factor, granulocyte macrophage colony stimulating factor, and granulocyte colony stimulating factor.

50. (Previously presented). The method of claim 47, wherein said antigen-presenting cell is selected from the group consisting of a fibroblast, a macrophage, a B cell, and a dendritic cell.

51. (Previously presented). The method of claim 47, wherein said tumor is a solid tumor or a hematological tumor.

52. (Previously presented). The method of claim 47, wherein said tumor is selected from the group consisting of melanoma, lymphoma, plasmacytoma, sarcoma, glioma, thymoma, leukemias, breast cancer, prostate cancer, colon cancer, esophageal cancer, brain cancer, lung cancer, ovarian cancer, cervical cancer and hepatoma.

53. (Previously presented). The method of claim 47, wherein said animal is a human subject.

54. (Previously presented). The method of claim 26, wherein said total genomic DNA is sheared.